Welcome to the Horizon 2020 atherosclerosis research program website
In line with the ground-breaking concept of REPROGRAM not only the cholesterol lowering PCSK9 inhibitors seem to be effective. But now, a purely anti-inflammatory cardiovascular trial with the IL-1ß blocker was positive. Thus, both hypotheses seem to be correct, the cholesterol and the inflammation hypotheses of treating cardiovascular disease. The global Phase III CANTOS
Sophie J. Bernelot Moens, junior researcher in the group of Prof. Erik Stroes and Prof. Menno de Winther (Academic Medical Center) recently published her results in European Heart Journal on how PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies increase hepatic low-density lipoprotein receptor expression and show potent low-density lipoprotein
The group of Prof. Catapano at University of Milano, Italy (IRCCS MultiMedica-MultiMedica SpA, Cardiovascular Department, Atherosclerosis Center) published an highly interesting review on the biological processes of Proprotein Convertase Subtilisin Kexin 9 (PCSK9). PCK9 is a key regulator of low-density lipoprotein receptor levels and LDL-cholesterol levels. The PCSK9 gene is associated with hypocholesterolaemia and protection against cardiovascular disease, setting the stage for
The first informal young REPROGRAM researcher meeting was held at the European Atherosclerosis Society in Prague. REPROGRAM provides an excellent environment for early stage researchers as it brings together senior researchers from different fields of expertise such as cardiovascular diseases, immunology and rheumatology, covering the spectrum of fundamental and clinical studies. Furthermore, life sciences companies are
The groups of Riksen, Joosten and Netea investigated the induction of trained immunity (innate immune memory) and the role of immune and metabolic pathways that result in epigenetic rewiring of cellular functional programs. Trained immunity is the key mechanism studied in REPROGRAM and proposed as a common diseases mechanism underlying atherosclerosis and rheumatoid arthritis. The study published in CELL
After a successful 1st REPROGRAM project year and most scientific work currently underway, an INFORMAL MEET-UP will be organized for all “YOUNG” REPROGRAM researchers at the 85th European Atherosclerosis Society congress held in Prague, Czech Republic (23-26 April, 2017). In REPROGRAM, 9 academic groups are involved that embed over 10 Postdoctoral researchers and 12 PhD students, all dedicated to the development of
Bekkering et al determined the optimal conditions for an in vitro experimental protocol of monocyte training using three of the most commonly used training stimuli from the literature: -glucan, BCG vaccine, and oxLDL. Although the effects of these three stimuli on trained immunity have been described before, this is the first time that the kinetics of this in vitro model have
On January 30, 2017, the 2nd Governing Council meeting took place in Munich. This meeting was convened by the Work package 2 leader (Esther Lutgens, Ludwig-Maximilians-Universität München) and hosted at the Hilton Conference center nearby Munich Airport. The consortium members widely discussed the detailed project activities and workplan (Work-Packages and Tasks) and the main objectives of the
On January 30, 2017, the 2nd REPROGRAM Governing Council meeting is organized in Munich, Germany. All consortium partners are invited. Beside progress presentations of each work package leader, networking and training activities are scheduled.
ERA-NET on Cardiovascular Diseases Joint Transnational Call for Proposals 2017 (JTC 2017): “Mechanisms of early atherosclerosis and/or plaque instability in Coronary Artery Disease” CVD research is not only a crucial area in health research overall, but could become an outstanding example of research driven innovation across Europe. An effective coordination of research at national
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.